Clinical edge intact, but Q1 miss clouds aggressive 30% recovery guidance

Delivered result confirms ₹19.4 Cr revenue vs ₹17.8 Cr in Q1 FY26 = 9.1% growth

Delivered ₹1.8 Cr PAT vs ₹3.1 Cr prior year = 42% decline, not modest moderation

EBITDA margin 12.5% vs 29% prior year (1,651 bps drop). Management claims ₹~2.95 Cr in expansion one-offs would yield adjusted margin 27.6%, but unverified

FY26 growth was 46%, FY25 was 48% — declining trend. 30% is LOWER than recent history, not higher

No contradictory evidence in results; clinical metrics not reported in financial statements, claim plausible

Opened July 16, 2026 (after Q1 ended June 30), so minimal Q1 contribution; future impact unproven

Q1 FY26 margin 29% → Q1 FY27 12.5%. Driven by SiD/ERICA marketing (pan-India), pre-ops at South Extension, clinical talent hiring. No specific prior quarter guidance to compare, but absolute level is weak.

FY26 growth 46%, FY25 48%, Q1 FY27 YoY growth 9.1%. Declining trend despite AI investment and expansion. Management attributes to Q1 seasonality and center construction.

First-attempt success rate rose to 62% from 58% prior baseline, driven by SiD/ERICA deployment (~8% improvement claimed in early results). First-mover moat in India per IVF 2.0 certification.

South Extension hub now operational (July 16, 2026). Gurgaon and Nagpur in 10-25 days. 10-hub target for FY27 on track, but execution risk on new-market ramp-up remains.

Q1/Q3 seasonally weak (heat, patient perceptions). Centers under construction, AI integration focus. New hubs will kick in Q2-Q4. Historical 30% YoY growth sustainable; industry CAGR 10-12%.

3-month breakeven historically vs 6-month guidance. Lucknow hospital core IVF + women's health extension. Lucknow is UP capital (untapped market), not diverting IPO proceeds, internal accruals funded.

USP is clinical excellence + SOP model + AI moat. ART Act enabling consolidation (30% organized → higher). Mushroom centers won't survive regs. 70% unorganized market consolidating toward leaders.

One-time heavy marketing push for SiD/ERICA pan-India. Strategic differentiator + clinical uplift. Expect reward rest of year. Yes, margins to recover to FY26 levels.

30% growth year-on-year. Sustain EBITDA and PAT. Historical 30% delivered, will replicate.

First in India (certified by US-based IVF 2.0). SiD assesses best sperm in real-time; ERICA rates embryos via 2.5M parameters. ~8% first-attempt success lift (early results, longer data needed). Standardizes embryologist skill across network.

Stated explicitly multiple times; based on historical ~30% track record and new hub ramp-ups. Q1 start of 9.1% means Q2-Q4 must average 40%+ to hit target—steep recovery required

FY26 margins ~29-30%. Q1 at 12.5% requires recovery to ~25-28% by Q4 to average ~20% for full FY27. Contingent on one-offs not recurring and hub ramp-ups reaching run-rate margins

Funded via IPO proceeds (hubs) + internal accruals (Lucknow). On track per management; 1 hub live, 2 more in pipeline

Q1 delivered 9.1% growth; 30% FY target requires 40%+ growth in Q2-Q4. Execution on 10 new hub ramp-ups in parallel poses concentration of risk. If Q2 disappoints, guidance will be withdrawn.

EBITDA margin collapsed 1,651 bps to 12.5%. Management attributes ₹~2.95 Cr to expansion one-offs (SiD/ERICA marketing, pre-ops, clinical hiring). If one-offs persist or competition forces price cuts, adjusted margin recovery narrative fails.

ART Act (2022) is in 'various stages' of implementation across states. Some have state boards and registrations; others lack bank accounts for fee transfers. Full implementation 1-2+ years away. Consolidation tailwind is contingent on effective enforcement.

Janakpuri (flagship) grows ~30% YoY and is 'still growing', per Dr. Khanna. But Q1 overall growth was 9.1%, implying older hubs are flat/negative or new cohort ramping slowly. New hub unit economics (30 cycles/year Tier 2 = ~₹60 lakhs/year revenue post-break-even) may not sustain 30% FY target.